Abstract
The efficacy of statins in lowering low-density lipoprotein cholesterol (LDL-C) and reducing coronary heart disease risk is well established; however, recent evidence suggests that more aggressive lipid management, even beyond achievement of currently recommended LDL-C goals, may provide additional clinical benefits. A novel approach to the aggressive lowering of LDL-C is the combination of statins with agents that affect different aspects of cholesterol metabolism. Because absorption of cholesterol is an important contributor to cholesterol balance, the simultaneous inhibition of cholesterol absorption and cholesterol synthesis is an attractive approach to achieving greater LDL-C reductions. In clinical trials, the combination of the cholesterol absorption inhibitor ezetimibe with a statin resulted in greater improvements in lipids than statin monotherapy and allowed a greater percentage of patients to achieve treatment goals. In addition, this combination may offer benefits through reduction of phytosterols, chylomicron remnants, and C-reactive protein. Several ongoing trials are evaluating whether the benefit of simultaneously blocking cholesterol synthesis and intestinal cholesterol absorption translates into better clinica...Continue Reading
References
Nov 16, 1995·The New England Journal of Medicine·J ShepherdC J Packard
Oct 3, 1996·The New England Journal of Medicine·F M SacksE Braunwald
Mar 26, 1998·The American Journal of Cardiology·P JonesD Hunninghake
Jun 5, 1998·JAMA : the Journal of the American Medical Association·J R DownsA M Gotto
Aug 7, 1998·European Journal of Clinical Investigation·S D Proctor, J C Mamo
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Mar 1, 2000·Archives of Internal Medicine·T A PearsonS Kafonek
Mar 14, 2001·European Journal of Pharmacology·M van HeekH R Davis
Apr 5, 2001·The American Journal of Medicine·H H KnappM H Davidson
Jul 11, 2001·Pharmacotherapy·R J StrakaA C Smith
Jul 13, 2002·Lancet·UNKNOWN Heart Protection Study Collaborative Group
Oct 9, 2002·Circulation·Thomas SudhopKlaus von Bergmann
Nov 9, 2002·The American Journal of Cardiology·Claude GagnéUNKNOWN Ezetimibe Study Group
Nov 15, 2002·The New England Journal of Medicine·Paul M RidkerNancy R Cook
Dec 19, 2002·Metabolism: Clinical and Experimental·Thomas SudhopKlaus von Bergmann
Dec 31, 2002·Journal of the American College of Cardiology·Michael H DavidsonEnrico P Veltri
Feb 15, 2003·The American Journal of Cardiology·Boris KerznerUNKNOWN Ezetimibe Study Group
Mar 19, 2003·Clinical Endocrinology·C A Dane-StewartT G Redgrave
Apr 26, 2003·European Heart Journal·Lorenzo MelaniUNKNOWN Ezetimibe Study Group
Apr 30, 2003·Circulation·Christie M BallantyneUNKNOWN Ezetimibe Study Group
Jul 5, 2003·The American Journal of Cardiology·Kathleen A FoleyCharles M Alexander
Dec 17, 2003·The American Journal of Cardiology·Philip T SagerUNKNOWN Ezetimibe Study Group
Jan 28, 2004·Circulation·Antoni PaulLawrence Chan
Feb 11, 2004·Circulation·G SalenUNKNOWN Multicenter Sitosterolemia Study Group
Mar 5, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN REVERSAL Investigators
Mar 10, 2004·The New England Journal of Medicine·Christopher P CannonUNKNOWN Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators